Avery T. Boice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Avery T. Boice has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Iris Yuwen Zhou
Athinoula A. Martinos Center for Biomedical Imaging
38 shared publications - Peter Caravan
Athinoula A. Martinos Center for Biomedical Imaging
38 shared publications - Hua Ma
Harvard Medical School
37 shared publications - Jonah Weigand-Whittier
Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts
37 shared publications - Andrew Scott Liss
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA
36 shared publications - Bahar Ataeinia
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St. White 427, Boston, MA 02114, USA
36 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S3. Dynamic tumor %nSI in PDAC6 tumor-bearing mice after injection of MnL3 or MnL4. MnL4 (0.1 mmol/kg, i.v.) only produced transient signal enhancement after injection, while MnL3 (0.1 mmol/kg, i.v.) produced persistent and higher signal enhancement in tumors. (n = 4 for each group).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S3. Dynamic tumor %nSI in PDAC6 tumor-bearing mice after injection of MnL3 or MnL4. MnL4 (0.1 mmol/kg, i.v.) only produced transient signal enhancement after injection, while MnL3 (0.1 mmol/kg, i.v.) produced persistent and higher signal enhancement in tumors. (n = 4 for each group).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S7. MnL3 molecular MRI of PANC1 tumor-bearing mice before administration of vehicle or FOLFIRINOX. After randomly assigning PANC1 mice to FOLFIRINOX or vehicle group, MnL3 molecular MRI (0.1 mmol/kg, i.v., 60 min p.i.) showed equivalent tumor enhancement before administration of vehicle or FOLFIRINOX. (n = 8 for each group, Student’s t-test, two-tailed, ns, not significant.).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S7. MnL3 molecular MRI of PANC1 tumor-bearing mice before administration of vehicle or FOLFIRINOX. After randomly assigning PANC1 mice to FOLFIRINOX or vehicle group, MnL3 molecular MRI (0.1 mmol/kg, i.v., 60 min p.i.) showed equivalent tumor enhancement before administration of vehicle or FOLFIRINOX. (n = 8 for each group, Student’s t-test, two-tailed, ns, not significant.).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S5. Immediate dynamic contrast enhanced (DCE) MRI in PDAC6 tumor with MnL4 performed before, at 3 days (1 dose FOLFIRNOX), or at 7 days (2 doses FOLFIRINOX) after the initiation of FOLFIRINOX treatment. Time course of change in normalized signal intensity acquired from DCE images with MnL4 as the probe (0.1 mmol/kg, i.v., n = 4 for each group, data shown as mean value with 95% simultaneous confidence bands as shaded regions). Data are superimposable at each time point measured, indicating no changes in tumor permeability or extracellular volume with FOLFIRINOX treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S5. Immediate dynamic contrast enhanced (DCE) MRI in PDAC6 tumor with MnL4 performed before, at 3 days (1 dose FOLFIRNOX), or at 7 days (2 doses FOLFIRINOX) after the initiation of FOLFIRINOX treatment. Time course of change in normalized signal intensity acquired from DCE images with MnL4 as the probe (0.1 mmol/kg, i.v., n = 4 for each group, data shown as mean value with 95% simultaneous confidence bands as shaded regions). Data are superimposable at each time point measured, indicating no changes in tumor permeability or extracellular volume with FOLFIRINOX treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S10. Quantification of manganese content in the 1319 tumor 60 minutes post-injection of MnL3. After randomly assigning 1319 mice to the vehicle or FOLFIRINOX group, MnL3 showed equivalent tumor uptake (0.1 mmol/kg, i.v., 60 min p.i., n = 5 for each group, Student’s t-test. ns: not significant).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S10. Quantification of manganese content in the 1319 tumor 60 minutes post-injection of MnL3. After randomly assigning 1319 mice to the vehicle or FOLFIRINOX group, MnL3 showed equivalent tumor uptake (0.1 mmol/kg, i.v., 60 min p.i., n = 5 for each group, Student’s t-test. ns: not significant).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S6. Quantification of manganese content in the PDAC6 tumor 60 minutes post-injection of MnL3. MnL3 (0.1 mmol/kg, i.v., 60 min p.i.) exhibited significantly higher tumor uptake at 3 days (P = 0.05) and 7 days (P = 0.04) after initiation of FOLFIRINOX treatment compared to the untreated tumor (One-way ANOVA with Tukey’s post hoc test, *P<0.05, ns, not significant. n = 6 for day 0 and day 3, n = 5 for day 7).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S6. Quantification of manganese content in the PDAC6 tumor 60 minutes post-injection of MnL3. MnL3 (0.1 mmol/kg, i.v., 60 min p.i.) exhibited significantly higher tumor uptake at 3 days (P = 0.05) and 7 days (P = 0.04) after initiation of FOLFIRINOX treatment compared to the untreated tumor (One-way ANOVA with Tukey’s post hoc test, *P<0.05, ns, not significant. n = 6 for day 0 and day 3, n = 5 for day 7).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S4. The PDAC6 tumor percentage change of normalized signal intensity (%nSI, normalized to an adjacent phantom) at 30 min p.i. of probe (n = 4 for each group). One-way ANOVA with Tukey’s post hoc test, *P<0.05, **P < 0.01, ns, not significant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S4. The PDAC6 tumor percentage change of normalized signal intensity (%nSI, normalized to an adjacent phantom) at 30 min p.i. of probe (n = 4 for each group). One-way ANOVA with Tukey’s post hoc test, *P<0.05, **P < 0.01, ns, not significant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Supplementary method, supplementary figure legends, and references.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Supplementary method, supplementary figure legends, and references.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S1. Mass spectra of MnL3 solutions before and after reaction with butyraldehyde. (A) MS spectrum of MnL3. [M + H]+ calcd for [C20H32MnN7O5], 505.2; found 505.0. (B) MS spectrum of the reaction product between MnL3 and butyraldehyde at pH 7.4 (PBS). [M + H]+ calcd for [C24H38MnN7O5], 559.2; found 559.5. (C) MS spectrum of the reaction product between MnL3 and butyraldehyde at pH 6.5(PBS).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S1. Mass spectra of MnL3 solutions before and after reaction with butyraldehyde. (A) MS spectrum of MnL3. [M + H]+ calcd for [C20H32MnN7O5], 505.2; found 505.0. (B) MS spectrum of the reaction product between MnL3 and butyraldehyde at pH 7.4 (PBS). [M + H]+ calcd for [C24H38MnN7O5], 559.2; found 559.5. (C) MS spectrum of the reaction product between MnL3 and butyraldehyde at pH 6.5(PBS).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S2. Mass spectra of MnL4 before and after incubation with butyraldehyde. (A) MS spectrum of MnL4. [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0. (B) MnL4 did not react with butyraldehyde at pH 7.4 (PBS). [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0). (C) MnL4 did not react with butyraldehyde at pH 6.5 (PBS). [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S2. Mass spectra of MnL4 before and after incubation with butyraldehyde. (A) MS spectrum of MnL4. [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0. (B) MnL4 did not react with butyraldehyde at pH 7.4 (PBS). [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0). (C) MnL4 did not react with butyraldehyde at pH 6.5 (PBS). [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S9. MnL3 molecular MRI of 1319 tumor-bearing mice before administration of vehicle or FOLFIRINOX. After randomly assigning 1319 mice to the vehicle or FOLFIRINOX group, MnL3 molecular MRI showed equivalent tumor enhancement before administration of vehicle or FOLFIRINOX. ( n = 4 for each group, Student’s t-test. ns: not significant).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Figure S9. MnL3 molecular MRI of 1319 tumor-bearing mice before administration of vehicle or FOLFIRINOX. After randomly assigning 1319 mice to the vehicle or FOLFIRINOX group, MnL3 molecular MRI showed equivalent tumor enhancement before administration of vehicle or FOLFIRINOX. ( n = 4 for each group, Student’s t-test. ns: not significant).